Home Life Sciences Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model
Article
Licensed
Unlicensed Requires Authentication

Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model

  • Matthias Koch , Klaus Bonaventura , Frank Spillmann , Andreas Dendorfer , Heinz-Peter Schultheiss and Carsten Tschöpe
Published/Copyright: May 15, 2008
Biological Chemistry
From the journal Volume 389 Issue 6

Abstract

Bradykinin (BK) coronary outflow and left ventricular (LV) performance of kininogen-deficient Brown Norway Katholiek (BNK) rats and Brown Norway Hannover (BNH) controls were investigated. We analyzed whether the angiotensin-converting enzyme (ACE) inhibitor ramipril is able to attenuate LV dysfunction after induction of myocardial infarction (MI) in this animal model. Ex vivo, the basal BK content in the coronary outflow of buffer-perfused, isolated hearts was measured by specific radioimmunoassay. In vivo, left ventricular pressure (LVP), the maximal rate of LVP increase, LV end-diastolic pressure, the maximal rate of LVP decrease and heart rate were determined using a tip catheter 3 weeks after induction of MI. Compared to BNK rats, basal BK outflow was increased 30-fold in controls (p<0.01). In vivo, we found no significant differences between sham-ligated BNK and BNH rats in basal LV function. After MI, the impairment of LV function was significantly worse in BNK rats when compared to BNH rats. ACE inhibition significantly attenuated this LV dysfunction in both groups, when compared to untreated animals. Reduced basal BK level resulting from kininogen deficiency has no effect on basal LV function, but remains to be a risk factor for the ischemic heart. However, ACE inhibition is sufficient to improve LV function despite kininogen deficiency.


Corresponding author

Received: 2007-10-31
Accepted: 2008-2-11
Published Online: 2008-05-15
Published in Print: 2008-06-01

©2008 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Editorial
  2. Kallikreins and kallikrein-related peptidases
  3. Guest Editorial
  4. The 2nd International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK 2007) and the Commemorative Gold Medal of the E.K. Frey–E. Werle Foundation of the Henning L. Voigt Family
  5. Highlight: Kallikrein, kinins and kallikrein-related peptidases
  6. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7
  7. Development of peptides specifically modulating the activity of KLK2 and KLK3
  8. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer
  9. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs)
  10. Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions
  11. A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology
  12. microRNAs: a new frontier in kallikrein research
  13. Functions of KLK4 and MMP-20 in dental enamel formation
  14. Genetic deficiency in tissue kallikrein activity in mouse and man: effect on arteries, heart and kidney
  15. Development of diabetic cardiomyopathy and the kallikrein-kinin system – new insights from B1 and B2 receptor signaling
  16. Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor
  17. Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model
  18. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia
  19. Kallikreins as microRNA targets: an in silico and experimental-based analysis
  20. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration
  21. Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids
  22. Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells
  23. Gene expression changes associated with the anti-angiogenic activity of kallikrein-related peptidase 3 (KLK3) on human umbilical vein endothelial cells
  24. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines
  25. Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung
Downloaded on 10.2.2026 from https://www.degruyterbrill.com/document/doi/10.1515/BC.2008.083/html
Scroll to top button